{
    "2020-09-30": [
        [
            {
                "time": "2018-03-15",
                "original_text": "AbbVie withdraws uterine fibroids drug from Canada",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "withdraws",
                        "uterine",
                        "fibroids",
                        "drug",
                        "Canada"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "US court voids $448 million award against AbbVie, AndroGel partner",
                "features": {
                    "keywords": [
                        "US",
                        "court",
                        "voids",
                        "$448",
                        "million",
                        "award",
                        "AbbVie",
                        "AndroGel"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "U.S. court voids $448 million award against AbbVie, but revives FTC claim over AndroGel",
                "features": {
                    "keywords": [
                        "U.S.",
                        "court",
                        "voids",
                        "$448",
                        "million",
                        "award",
                        "AbbVie",
                        "FTC",
                        "claim",
                        "AndroGel"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Better Buy: CRISPR Therapeutics vs. Editas Medicine",
                "features": {
                    "keywords": [
                        "Better",
                        "Buy",
                        "CRISPR",
                        "Therapeutics",
                        "Editas",
                        "Medicine"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Oxford to study anti-inflammatory drug Humira as potential COVID-19 treatment",
                "features": {
                    "keywords": [
                        "Oxford",
                        "study",
                        "anti-inflammatory",
                        "drug",
                        "Humira",
                        "COVID-19",
                        "treatment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}